Methods of delivering DLL3 antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-9878053-B2
Application number	US-201715608991-A
Country	US
Kind code	B2
Filing date	May 30, 2017
Priority date	Feb 24, 2012
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. A method of delivering a pyrrolobenzodiazepine (PBD) to a DLL3 expressing cancer cell in a subject, the method comprising contacting the cell with a therapeutically effective amount of an antibody drug conjugate (ADC), or a pharmaceutically acceptable salt thereof, wherein the antibody drug conjugate comprises the formula M-[L-D]n, wherein:
M comprises a humanized anti-DLL3 antibody comprising a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
L comprises a linker;
D comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O SO 2 R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted; and
n is an integer from 1 to 20.

2. The method of claim 1 , wherein the cancer cell is a lung cancer cell.

3. The method of claim 2 , wherein the lung cancer cell is a small cell lung cancer cell.

4. The method of claim 1 , wherein the cancer cell is a large cell neuroendocrine carcinoma cell.

5. The method of claim 1 , wherein the cancer cell is a thyroid cancer cell.

6. The method of claim 1 , wherein the cancer cell is a prostate cancer cell.

7. The method of claim 1 , wherein the contacting is performed in vitro.

8. The method of claim 1 , wherein the contacting is performed in vivo.

9. The method of claim 1 , wherein:
R 2 is R, wherein R is a C 5-20 aryl group;
R 6 and R 9 are H;
R 7 is OR, and wherein R is a C 1 alkyl;
Q is O, and wherein R 11 is H; and/or
X and X″ are O.

10. The method of claim 9 , wherein R 2 is R, wherein R is a C 5-20 aryl group.

11. The method of claim 9 , wherein R 6 and R 9 are H.

12. The method of claim 9 , wherein R 7 is OR.

13. The method of claim 12 , wherein R is a C 1 alkyl.

14. The method of claim 9 , wherein Q is O.

15. The method of claim 14 , wherein R 11 is H.

16. The method of claim 9 , wherein X and X″ are O.

17. A method of determining cytotoxicity of an anti-DLL3 antibody drug conjugate (ADC), or a pharmaceutically acceptable salt thereof, the method comprising the steps of:
(a) contacting a cancer cell with the antibody drug conjugate, wherein the antibody drug conjugate comprises the formula M-[L-D]n, wherein:
M comprises a humanized anti-DLL3 antibody comprising a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
L comprises a linker;
D comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O SO 2 R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted; and
n is an integer from 1 to 20; and
(b) determining killing of the cancer cell.

18. The method of claim 17 , wherein the cancer cell is a lung cancer cell.

19. The method of claim 18 , wherein the lung cancer cell is a small cell lung cancer cell.

20. The method of claim 17 , wherein the cancer cell is a large cell neuroendocrine carcinoma cell.

21. The method of claim 17 , wherein the contacting is performed in vitro.

22. The method of claim 17 , wherein the contacting is performed in vivo.

23. The method of claim 17 , wherein:
R 2 is R, wherein R is a C 5-20 aryl group;
R 6 and R 9 are H;
R 7 is OR, and wherein R is a C 1 alkyl;
Q is O, and wherein R 11 is H; and/or
X and X″ are O.

24. The method of claim 23 , wherein R 2 is R, wherein R is a C 5-20 aryl group.

25. The method of claim 23 , wherein R 6 and R 9 are H.

26. The method of claim 23 , wherein R 7 is OR.

27. The method of claim 26 , wherein R is a C 1 alkyl.

28. The method of claim 23 , wherein Q is O.

29. The method of claim 28 , wherein R 11 is H.

30. The method of claim 23 , wherein X and X″ are O.

Assignees

• Abbvie Stemcentrx Llc

Inventors

• Stull Robert A
• Saunders Laura
• Dylla Scott J
• Foord Orit
• Liu David
• Torgov Michael
• Shao Hui

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5752

  of the lungs · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title